Valitor has announced promising preclinical data on VLTR-559, a novel long-acting anti-VEGF biologic aimed at treating wet age-related macular degeneration (AMD) with a twice-yearly dosing regimen. This development will be presented at the upcoming ARVO Annual Meeting on May 3, 2026. VLTR-559 leverages Valitor’s proprietary multivalent polymer (MVP) technology, which enhances the pharmacokinetic and pharmacodynamic properties of the drug, allowing it to remain in ocular tissues, such as the retina, three to four times longer than first-generation anti-VEGF therapies.

The significance of VLTR-559 lies in its potential to reduce the burden of frequent intravitreal injections that patients currently face, which are necessary to maintain efficacy over time. Preclinical studies indicate that VLTR-559 not only matches the safety and efficacy profiles of existing treatments but also offers unprecedented durability at the target site without compromising potency. This could lead to improved patient adherence and outcomes, as fewer office visits would be required for monitoring and treatment.

The implications of this development are substantial for the field of ophthalmology and longevity research. By demonstrating a reliable long-acting formulation, Valitor may shift the paradigm in AMD treatment, paving the way for similar long-acting therapies across other indications. This advancement could accelerate timelines for drug development in aging-related diseases, as the MVP technology platform allows for tailored modifications that enhance both efficacy and safety, potentially leading to broader applications in chronic conditions associated with aging.

Source: globenewswire.com